Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Candela, Ana
  • Santamarina-Fernández, Rebeca
  • Avendaño-Ortiz, José
  • Martínez-Alonso, Emma
  • Oviaño, Marina
  • Cantón, Rafael
  • Arenas, Jesús
  • Moscoso, Miriam
  • Bou, Germán
[Abstract] Introduction: Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). Methods: To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. Results: All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Discussion: Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa., The author(s) declared that financial support was received for this work and/or its publication. This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, and the projects PI18/00501 and PI21/00704 to GB, and the project PI20/00686 to MO, integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013–2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. In addition, this work was supported by the Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 and, as appropriate, by ERDF A way of making Europe by the European Union or by the European Union Next Generation EU/PRTR (Grant agreement PID2020-114617RB-100) to JA. VF-V was funded with a predoctoral fellowship from the Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012) and by the Spanish Society of Clinical Microbiology and Infectious Diseases (SEIMC) for a research stay (May-July 2022) at the University of Zaragoza. AC was financially supported by the Río Hortega program (ISCIII-SERGAS, CM21/00165).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

LpxR and PagL expression in live attenuated auxotrophic Pseudomonas aeruginosa vaccines modulates lipid A reactogenicity in vitro while preserving immunogenicity

  • Moscoso, Miriam
  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Vallejo, J. A.
  • Pérez-Ortega, Jesús
  • Santamarina-Fernández, Rebeca
  • Candela, Ana
  • Oviaño, Marina
  • Arenas, Jesús
  • Bou, Germán
[Abstract] Introduction: Pseudomonas aeruginosa is a Gram-negative opportunistic pathogen responsible for severe respiratory tract infections. We previously developed a live attenuated auxotrophic vaccine candidate, PAO1 ΔmurI, which conferred protection in murine infection models but exhibited significant reactogenicity when administered intranasally. To reduce the toxicity of PAO1 ΔmurI without compromising its protective efficacy, we engineered strains with a modified lipid A structure, as lipid A is one of the main toxic components of whole-cell vaccines. Methods: Two lipid A-modifying enzymes, LpxR and PagL were overproduced in PAO1 ΔmurI derivatives. The resulting lipopolysaccharide (LPS) was analyzed by MALDI-TOF mass spectrometry. In vitro assays with HEK293-Blue reporter cells expressing murine and human Toll-like receptor 4 (TLR4) were used to assess LPS-associated toxicity, while in vivo reactogenicity and protective efficacy were evaluated in a murine acute pneumonia model. Results: LPS extracted from the wild-type strain showed heterogeneous lipid A structures with varying degrees of acylation, and a predominant penta-acylated species. Expression of LpxR led to enrichment in tetra-acylated species, while PagL expression reduced the heterogeneity observed in the wild type. Both mutant strains showed decreased TLR4 activation in vitro as compared to the wild type. In mice, lipid A-modified derivatives retained protective efficacy; however, no reduction in reactogenicity was observed. Discussion: Lipid A modifications mediated by LpxR and PagL attenuated TLR4 signaling in vitro but were insufficient to reduce in vivo reactogenicity. Additional modifications or targeting of other toxic components may be required. This strategy may serve as an initial basis for optimizing live attenuated P. aeruginosa vaccines, although additional approaches will likely be necessary to achieve substantial improvements., This work was supported by a grant from the SERGAS-Galician Healthcare Service (Program “Innova Saúde”), CIBERINFEC, and the projects PI18/00501 and PI21/00704 to G.B., and the project PI20/00686 to M.O., integrated in the National Plan for Scientific Research, Development and Technological Innovation 2013-2016 from the Ministry of Economy and Competitiveness and the Institute of Health Carlos III. In addition, this work was supported by the Ciencia e Innovación/Agencia Española de Investigación MCIN/AEI/10.13039/501100011033 and, as appropriate, by ERDF A way of making Europe by the European Union or by the European Union Next Generation EU/PRTR (Grant agreement PID2020-114617RB-100) to J.A. V.F-V. was funded with a predoctoral fellowship from Conselleria de Cultura, Xunta de Galicia (IN606A-2019/012). A.C. was financially supported by the Río Hortega program (ISCIII-SERGAS, CM21/00165).
RUC. Repositorio da Universidade da Coruña
Publicación Artículo científico (JournalArticle)

In vitro susceptibility to imipenem/relebactam and comparators in a multicentre collection of mycobacterium abscessus complex isolates

  • Seoane-Estévez, Alejandro
  • Aja-Macaya, Pablo
  • García-Pose, Andrea
  • López-Roa, Paula
  • Ruedas-López, Alba
  • González-Galán, Verónica
  • Esteban, Jaime
  • Arca-Suárez, Jorge
  • Pampín, Martín
  • Beceiro Casas, Alejandro
  • Oviaño, Marina
  • Bou, Germán
[Abstract] Background and Objectives: Infections caused by non-tuberculous mycobacteria (NTM), including Mycobacterium abscessus complex (MABc), are increasing globally and are notoriously difficult to treat due to the intrinsic resistance of these bacteria to many common antibiotics. The aims of this study were to demonstrate the in vitro activity of imipenem/relebactam against MABc clinical isolates and to determine any in vitro synergism between imipenem/relebactam and other antimicrobials. Methods: A nationwide collection of 175 MABc clinical respiratory isolates obtained from 24 hospitals in Spain (August 2022–April 2023) was studied. Fifteen different antimicrobial agents were comprised, including imipenem/relebactam. MICs were determined according to CLSI criteria, and the synergism studies were performed with the selected clinical isolates. Results: Of the 175 isolates obtained, 110 were identified as M. abscessus subsp. abscessus (62.9%), 51 as M. abscessus subsp. massiliense (29.1%), and 14 as M. abscessus subsp. bolleti (8%). The antibiotics yielding the highest susceptibility rates were tigecycline, eravacycline, and omadacycline (100%); followed by imipenem/relebactam and clofazimine (97.6%); and finally amikacin (94.6%). Only four isolates were resistant to imipenem/relebactam, three of which were further characterized by WGS, revealing MABc mutations in BlaMab as well as D,D- and L,D-transpeptidades and mspA porin, which may play an important role in reduced susceptibility to imipenem/relebactam, even though none were previously described or associated with resistance to β-lactams. Conclusions: Our data demonstrate that relebactam improved the anti-MABc activity of imipenem, representing a β-lactam for the treatment of MABc infections. Furthermore, imipenem/relebactam demonstrated in vitro synergism with other anti-MABc treatments, thus supporting its use as part of dual regimens., This research was supported by the Instituto de Salud Carlos III (ISCIII, projects PI22/01212 to J.A.S., PI20/00686 to MO and PI21/00704 to GB) and co-funded by the European Union. The research was also supported by Merck Sharp & Dohme (MSD) through the Investigator Initiated Studies Program. The study was also funded by Centro de Investigación Biomédica en Red de Enfermedades Infecciosas (CIBERINFEC, CB21/13/00055) and by the Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Economía, Emprego e Industria (IN607A to G.B.). The study was also funded by the Axencia Galega de Innovación (GAIN), Consellería de Innovación, Consellería de Emprego e Industria trough “Proxectos de excelencia” IN607D2021/12 to A.B and IN607D2024/008 to J.A.S. A.S.E. was financially supported by the Rio Hortega program (ISCIII, CM21/00230) and J.A.S. was financially supported by the Juan Rodés program (ISCIII, JR21/00026). The Fundación Pública Galega de Investigación Biomédica INIBIC has paid the charges for the open access of the manuscript.
Zaguán. Repositorio Digital de la Universidad de Zaragoza
Publicación Artículo científico (JournalArticle)

Engineering low-endotoxin lipid A in a double auxotroph Pseudomonas aeruginosa to develop safer whole-cell vaccines

  • Fuentes-Valverde, Víctor
  • García, Patricia
  • Candela, Ana
  • Santamarina-Fernández, Rebeca
  • Avendaño-Ortiz, José
  • Martínez-Alonso, Emma
  • Oviaño, Marina
  • Cantón, Rafael
  • Arenas, Jesús
  • Moscoso, Miriam
  • Bou, Germán
Introduction: Pseudomonas aeruginosa is a highly adaptable Gram-negative bacterium causing severe respiratory infections, particularly in vulnerable populations. The rise of antimicrobial resistance highlights the urgent need for effective vaccines. We previously developed a live-attenuated vaccine candidate, PAO1 ΔmurI Δalr ΔdadX, a genetically stable double auxotrophic strain that exhibited dose-dependent reactogenicity upon intranasal administration in mice, likely due to lipid A component of lipopolysaccharide (LPS). Methods: To reduce LPS-associated toxicity while preserving immunogenicity, we engineered novel strains by inactivating genes involved in lipid A biosynthesis (htrB1, htrB2) or modification (pagP, pagL). Lipid A structural modifications were confirmed by MALDI-TOF MS. Mutants were evaluated for Toll-like receptor 4 (TLR4) activation, virulence attenuation, and their ability to induce immune responses and protection in an acute pneumonia model. Results: All engineered strains displayed modified lipid A structures. Mutations in htrB1 and htrB2 reduced TLR4 activation and significantly attenuated virulence following intraperitoneal challenge in mice. Inactivation of pagL resulted in minimal attenuation, whereas pagP inactivation led to marked attenuation without altering TLR4 activation. In the acute pneumonia model, all mutants elicited robust systemic and mucosal immune responses, and conferred strong protection, despite transient weight loss following intranasal administration. Discussion: Targeted lipid A modification represents an effective strategy to reduce in vitro reactogenicity while preserving immunogenicity in live-attenuated P. aeruginosa vaccine candidates. Although further optimization may minimize residual in vivo effects, these findings support the potential of engineered strains as vaccine candidates for preventing respiratory infections caused by P. aeruginosa.